October 27, 2015—A bipartisan group of U.S. Senators has asked the Federal Trade Commission to investigate whether makers of generic intravenous saline solution have colluded to exploit a shortage in order to boost profits.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)